Romanian Registry of Hypertrophic Cardiomyopathy – overview of general characteristics and therapeutic choices at a national level

Abstract Introduction. Hypertrophic cardiomyopathy (HCM) is a disease with increased left ventricular (LV) wall thickness not solely explained by abnormal loading conditions, with great heterogeneity regarding clinical expression and prognosis. The aim of the present study was to collect data on HCM patients from different centres across the country, in order to assess the general characteristics and therapeutic choices in this population. Methods. Between December 2014 and April 2017, 210 patients from 11 Romanian Cardiology centres were enrolled in the National Registry of HCM. All patients had to fulfil the diagnosis criteria for HCM according to the European Society of Cardiology guidelines. Clinical, electrocardiographic, imaging and therapeutic characteristics were included in a predesigned online file. Results. Median age at enrolment was 55 ± 15 years with male predominance (60%). 43.6% of the patients had obstructive HCM, 50% non-obstructive HCM, while 6.4% had an apical pattern. Maximal wall thickness was 20.3 ± 4.8 mm (limits 15-37 mm) while LV ejection fraction was 60 ± 8%. Heart failure symptoms dominated the clinical picture, mainly NYHA functional class II (51.4%). Most frequent arrhythmias were atrial fibrillation (28.1%) and non-sustained ventricular tachycardia (19.9%). Mean sudden cardiac death risk score (SCD-RS) was 3.0 ± 2.3%, with 10.4% of the patients with high risk of SCD. However, only 5.7% received an ICD. Patients were mainly treated with beta-blockers (72.9%), diuretics (28.1%) and oral anticoagulants (28.6%). Invasive treatment of LVOT obstruction was performed in a small number of patients: 22 received myomectomy and 13 septal ablation. Cardiac magnetic resonance was reported in only 14 patients (6.6%). Conclusions. The Romanian registry of HCM illustrates patient characteristics at a national level as well as the gaps in management which need improvement – accessibility to high-end diagnostic tests and invasive methods of treatment.

[1]  L. Tavazzi,et al.  The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies , 2018, European heart journal.

[2]  J. Moon,et al.  Update on hypertrophic cardiomyopathy and a guide to the guidelines , 2016, Nature Reviews Cardiology.

[3]  L. Tavazzi,et al.  European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of Cardiology. , 2016, European heart journal.

[4]  Martin Borggrefe,et al.  [2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy]. , 2014, Kardiologia polska.

[5]  F. Rutten,et al.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.

[6]  P. Elliott,et al.  Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review , 2013, Heart.

[7]  M. Maron,et al.  Controversies in cardiovascular medicine Pharmacological treatment options for hypertrophic cardiomyopathy : high time for evidence , 2012 .

[8]  M. Desai,et al.  Cardiac magnetic resonance in hypertrophic cardiomyopathy. , 2011, JACC. Cardiovascular imaging.

[9]  M. Sheppard,et al.  Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy using cardiovascular magnetic resonance , 2010 .

[10]  M. Link,et al.  Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction , 2006, Circulation.

[11]  A. Gavazzi,et al.  The Italian Registry for hypertrophic cardiomyopathy: a nationwide survey. , 2005, American heart journal.

[12]  M. Link,et al.  Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[13]  B. Maron,et al.  Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[14]  P. Elliott,et al.  Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. , 2003, Journal of the American College of Cardiology.

[15]  B. Maron Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[16]  B. Maron,et al.  Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy , 2001, Circulation.

[17]  W. Weaver Results of the RAPID 1 and RAPID 2 thrombolytic trials in acute myocardial infarction. , 1996, European heart journal.

[18]  H. Mcintosh,et al.  Ethics in cardiovascular medicine. Task Force II: The relation of cardiovascular specialists to patients, other physicians and physician-owned organizations. , 1990, Journal of the American College of Cardiology.

[19]  D. Waters,et al.  Long-term prognosis after myocardial infarction in patients with previous coronary artery bypass surgery. , 1988, Journal of the American College of Cardiology.

[20]  K. Huynh Hypertension: SPRINTing towards a new target for blood-pressure control , 2016, Nature Reviews Cardiology.